All In Biotech

Drug Trial Radar · NCT02476942

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

A Multicenter, Non-Interventional Study Evaluating Bleeding Incidence, Health-Related Quality of Life, and Safety in Patients With Hemophilia A Under Standard-of-Care Treatment

Last checked: Nov 19, 2026Latest source record: May 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

221

Actual

Start

May 26, 2015

Primary completion

Mar 31, 2017

Study completion Mar 31, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 22, 2015

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, HRQoL, and safety in patients with hemophilia A with or without FVIII inhibitors treated according to local routine clinical practice (receiving FVIII replacement or bypassing agents as either episodic or prophylactic treatment). Actual patients will be enrolled from routine clinical practice in this observational study.

Conditions

  • Hemophilia A

Interventions

  • Bypassing AgentsDrug

    Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.

  • FVIII ReplacementDrug

    Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of BleedsTime frame: Approximately 6 months (from Baseline until study completion)

Locations

35 sites in 12 countries. Site status is shown where the registry gives one.

  • Santa Monica Oncology Center

    Santa Monica, California

  • University of Colorado Denver, Children's Hospital

    Aurora, Colorado

  • Georgetown Uni Medical Center; Lombardi Cancer Center

    Washington D.C., District of Columbia

  • Winship Cancer Institute

    Atlanta, Georgia

  • Tulane Uni Health Sciences Center

    New Orleans, Louisiana

  • Children's Hospital of Michigan; Pediatrics

    Detroit, Michigan

  • Cornell Univ Medical College; Hematology-Oncolog

    New York, New York

  • Oregon Health & Science Uni ; Dept of Pediatrics

    Portland, Oregon

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia

    Seattle, Washington

  • Royal Prince Alfred Hospital; Haematology

    Camperdown, New South Wales, Australia

  • The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit

    Melbourne, Victoria, Australia

  • Peking Union Medical College Hospital

    Beijing, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China

  • Tianjin Institute of Hematology & Blood Diseases Hospital

    Tianjin, China

  • ICIC

    San José, Costa Rica

  • Universitätsklinikum Bonn (AöR); Inst. für Experimentelle Hämatologie u. Transfusionsmedizin (IHT)

    Bonn, Germany

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"

    Milan, Lombardy, Italy

  • AOU Careggi; SOD Malattie Emorragiche

    Florence, Tuscany, Italy

  • Nagoya University Hospital

    Aichi, Japan

  • Hyogo College of Medicine Hospital

    Hyōgo, Japan

  • St. Marianna University School of Medicine Hospital

    Kanagawa, Japan

  • Hospital of the University of Occupational and Environmental Health,Japan

    Kitakyushu-shi, Japan

  • Nara Medical University Hospital

    Nara, Japan

  • Tokyo Medical University Hospital

    Tokyo, Japan

  • Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii

    Gdansk, Poland

  • SPSK Nr1 Klinika Hematoo&Transpl.Szpiku

    Lublin, Poland

  • ALVAMED Lekarskie Gabinety Specjalistyczne

    Poznan, Poland

  • Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych

    Warsaw, Poland

  • Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center

    Johannesburg, South Africa

  • Severance Hospital

    Seoul, South Korea

  • Hospital Universitario la Paz; Servicio de Hematologia

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia

    Seville, Spain

  • Hospital Universitario la Fe; Servicio de Hematologia

    Valencia, Spain

  • National Taiwan Uni Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.